Dyadic International (NASDAQ:DYAI) Share Price Passes Below Fifty Day Moving Average – Time to Sell?

Dyadic International, Inc. (NASDAQ:DYAI) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.64 and traded as low as $1.37. Dyadic International shares last traded at $1.50, with a volume of 114,192 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Stock Up 6.4 %

The company has a market cap of $44.39 million, a price-to-earnings ratio of -6.52 and a beta of 0.89. The business has a 50-day simple moving average of $1.64 and a two-hundred day simple moving average of $1.41. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Two Sigma Securities LLC acquired a new position in Dyadic International during the fourth quarter valued at approximately $25,000. Millennium Management LLC bought a new stake in shares of Dyadic International during the 4th quarter worth $28,000. Jane Street Group LLC bought a new stake in shares of Dyadic International during the 4th quarter worth $45,000. Bank of America Corp DE grew its stake in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Finally, Inlet Private Wealth LLC bought a new position in Dyadic International in the 4th quarter worth $52,000. 27.95% of the stock is owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.